Withdrawal of application of pirfenidone (Esbriet) for treatment of unclassifiable interstitial lung disease

Withdrawal of application was based on the European Medical Agency’s requirement for further justification and robustness of data and clarity with the wording of the proposed indication.

European Medicines Agency